help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merchav, S.
Right arrow Articles by Skottner, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merchav, S.
Right arrow Articles by Skottner, A.

Journal of Clinical Endocrinology & Metabolism, Vol 74, 447-452, Copyright © 1992 by Endocrine Society

ARTICLES

Comparative studies of the erythroid-potentiating effects of biosynthetic human insulin-like growth factors-I and -II

S Merchav, I Silvian-Drachsler, I Tatarsky, M Lake and A Skottner
Department of Hematology, Technion Faculty of Medicine, Rappaport Family Institute for Research in the Medical Sciences, Haifa, Israel.

The erythroid-potentiating effects of biosynthetic human insulin-like growth factor-I (IGF-I) and IGF-II were evaluated and compared in serum- free cultures of human marrow erythroid progenitors. IGF-I and IGF-II enhanced the in vitro growth of relatively mature (CFU-E) and primitive (BFU-E) erythroid progenitors at similar dose-dependent magnitudes. Significant elevations in erythroid colony counts were detected at 0.2- 0.6 ng/mL of both peptides, with a maximal increase in CFU-E and BFU-E numbers detected at 2-6 ng/mL. Similar enhancement of erythroid progenitor cell growth by both peptides was also detected in cultures of marrow cells that had been depleted of accessory cells or in cultures of highly enriched hemopoietic progenitors. IGF-I and IGF-II enhanced erythroid progenitor cell growth at both limiting and saturating concentrations of recombinant human erythropoietin or granulocyte-macrophage colony-stimulating factor, but did not alter the sensitivity of CFU-E and BFU-E to their respective hemopoietic regulators. The erythroid-potentiating effects of IGF-I and IGF-II were completely abrogated by monoclonal antibodies directed against IGF-I membrane receptors. IGF-I and IGF-II thus appear to exert their effects on human marrow erythroid progenitors via a direct mechanism involving the type I IGF receptor.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
T. Kucic, I. B. Copland, J. Cuerquis, D. L. Coutu, L. E. Chalifour, R. F. Gagnon, and J. Galipeau
Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia
Am J Physiol Renal Physiol, August 1, 2008; 295(2): F488 - F496.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. M. Morison, M. R. Eccles, and A. E. Reeve
Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis
Blood, November 1, 2000; 96(9): 3023 - 3028.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society